Study Population
ONCOLOGY, DISEASE, FALLOPIAN TUBE CANCER
A single-institution, clinical trial was approved by the City of Hope Institutional Review Board (NCT01970722) to evaluate feasibility and safety of HIPEC with cisplatin in EOC and EC patients. All research was carried out in accordance with ethical principles as defined by the Declaration of Helsinki.Eligible patients had newly diagnosed or recurrent stage III/IV EOC, primary peritoneal, fallopian tube cancer, or EC. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and preexisting normal renal function. Patients were allowed to have received neoadjuvant chemotherapy before planned HIPEC. Complete or optimal gross resection of disease defined by R classification was required to be anticipated, as judged by participating surgeons.